<DOC>
	<DOCNO>NCT01381887</DOCNO>
	<brief_summary>The purpose study evaluate effect canagliflozin post-meal glucose blood level patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>A Study Evaluate Effect JNJ-28431754 ( Canagliflozin ) Post-Meal Glucose Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This double-blind ( neither study staff patient know identity treatment assign ) study canagliflozin patient Type 2 Diabetes Mellitus ( T2DM ) currently take metformin stable dose &gt; =1500 mg/day . Patients participate study approximately 16 week . During study , patient receive 4 treatment ( A , B , C , D ) ; treatment administer 3-day treatment period . Patients receive 1 dose study medication morning Day 1 Day 2 treatment period treatment period separate approximately 2 week . Treatments consist placebo ( A ) , canagliflozin 300 mg placebo ( B ) , canagliflozin 300mg ( C ) , canagliflozin 300mg canagliflozin 150mg ( D ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients T2DM inadequate glycemic control ( base upon fast glucose measurement &gt; =130 mg/dL &lt; =250 mg/dL ) metformin monotherapy metformin dual combination glucose lower agent ( sulphonylurea [ SU ] meglitinide dipeptidyl peptidase4 [ DPP4 ] inhibitor ) eligible enrollment study . History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy history severe hypoglycemic episode within 6 month screen Has repeat ( ie , 2 1week period ) fast plasma glucose ( FPG ) and/or fast selfmonitored blood glucose ( SMBG ) measurement &gt; =250 mg/dL ( 13.88 mmol/L ) pretreatment phase , despite reinforcement diet exercise counsel History current illness consider clinically significant investigator</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>